Efficacy of Triplet Combination Chemotherapy with Oxaliplatin, Irinotecan and Capecitabine (OCX) in Metastatic Colorectal Cancer in Relation to RAS/RAF Mutation Status: Results of a Retrospective Analysis

Publisher： Karger

E-ISSN： 2296-5262|37|11|646-652

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.37, Iss.11, 2014-10, pp. : 646-652

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Oxaliplatin, Irinotecan and Capecitabine (OCX) for First-Line Treatment of Advanced/Metastatic Colorectal Cancer: A Phase I Trial (SAKK 41/03)

By  

Oncology Research and Treatment, Vol. 33, Iss. 6, 2010-05 ,pp. : 295-299

Karger

Access to resources Recommend Favorite

Phase II Trial of Cetuximab plus Irinotecan for Oxaliplatin- and Irinotecan-Based Chemotherapy-Refractory Patients with Advanced and/or Metastatic Colorectal Cancer: Evaluation of Efficacy and Safety Based on KRAS Mutation Status (T-CORE0801)

By  

Oncology, Vol. 87, Iss. 1, 2014-06 ,pp. : 7-20

Karger

Access to resources Recommend Favorite

Efficacy of Treatment with Irinotecan and Oxaliplatin Combination in FU-Resistant Metastatic Colorectal Cancer Patients

By  

Oncology, Vol. 66, Iss. 2, 2004-05 ,pp. : 132-137

Karger

Access to resources Recommend Favorite

Irinotecan: New Results in the Combination Chemotherapy of Colorectal Cancer

By  

Oncology Research and Treatment, Vol. 23, Iss. 4, 2000-05 ,pp. : 8-14

Karger

Access to resources Recommend Favorite

Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II Trials

By  

Oncology Research and Treatment, Vol. 36, Iss. 6, 2013-05 ,pp. : 363-367

Karger

Access to resources Recommend Favorite